www.fdanews.com/articles/159679-jjs-janssen-buys-rights-to-hepatitis-c-compound-from-gsk

J&J’s Janssen Buys Rights to Hepatitis C Compound from GSK

October 10, 2013

Johnson & Johnson’s Janssen subsidiary has acquired GlaxoSmithKline’s GSK2336805, a daily replication complex inhibitor aimed at treating hepatitis C.
Genetic Engineering & Biotechnology News